Mercaptopurine, Imatinib — Competitive Intelligence Brief

Mercaptopurine, Imatinib (Mercaptopurine, Imatinib) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Purine analog antimetabolite and tyrosine kinase inhibitor combination. Area: Oncology.

phase 3 Purine analog antimetabolite and tyrosine kinase inhibitor combination Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib) Oncology Small molecule

Target snapshot

Mercaptopurine, Imatinib (Mercaptopurine, Imatinib) — St. Jude Children's Research Hospital. Mercaptopurine and imatinib work together as a combination therapy: mercaptopurine is a purine analog that inhibits nucleotide synthesis to kill rapidly dividing cells, while imatinib is a tyrosine kinase inhibitor that blocks BCR-ABL and other oncogenic kinases.

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mercaptopurine, Imatinib TARGET	Mercaptopurine, Imatinib	St. Jude Children's Research Hospital	phase 3	Purine analog antimetabolite and tyrosine kinase inhibitor combination	Purine metabolism enzymes (mercaptopurine); BCR-ABL, c-KIT, PDGFR (imatinib)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Purine analog antimetabolite and tyrosine kinase inhibitor combination class)

1. St. Jude Children's Research Hospital · 1 drug in this class